References
- Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M, et al. Impact of new antiretroviral combination therapies in HIV-infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. Br Med J 1997; 315: 1194–9
- Palella FJ, Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853–60
- Mocroft A, Miller V, Chiesi A, Blaxhult A, Katlama C, Clotet B, et al. Virological failure among patients on HAART from across Europe: results from the EuroSIDA study. Antivir Ther 2000; 5: 107–12
- Aarnoutse RE, Schapiro JM, Boucher CA, Hekster YA, Burger DM. Therapeutic drug monitoring: an aid to optimizing response to antiretroviral drugs?. Drugs 2003; 63: 741–53
- Back D, Gatti G, Fletcher C, Garaffo R, Haubrich R, Hoetelmans R, et al. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS 2002; 16(Suppl 1)S5–37
- Duong M, Golzi A, Peytavin G, Piroth L, Froidure M, Grappin M, et al. Usefulness of therapeutic drug monitoring of antiretrovirals in routine clinical practice. HIV Clin Trials 2004; 5: 216–23
- Gerber JG, Acosta EP. Therapeutic drug monitoring in the treatment of HIV infection. J Clin Virol 2003; 27: 117–28
- Piscitelli SC. The role of therapeutic drug monitoring in the management of HIV-infected patients. Curr Infect Dis Rep 2002; 4: 353–8
- Antinori A, Cozzi-Lepri A, Ammassari A, Trotta MP, Nauwelaers D, Hoetelmans R, et al. Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART. Antivir Ther 2004; 9: 291–6
- Bossi P, Peytavin G, Ait-Mohand H, Delaugerre C, Ktorza N, Paris L, et al. GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. HIV Med 2004; 5: 352–9
- Burger D, Hugen P, Reiss P, Gyssens I, Schneider M, Kroon F, et al. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS 2003; 17: 1157–65
- Clevenbergh P, Garraffo R, Durant J, Dellamonica P. PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results. AIDS 2002; 16: 2311–5
- De Maat MM, Huitema AD, Mulder JW, Meenhorst PL, van Gorp EC, Mairuhu AT, et al. Sub-therapeutic antiretroviral plasma concentrations in routine clinical outpatient HIV care. Ther Drug Monit 2003; 25: 367–73
- 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41:1–19.
- Mallon PW, Ray J, Cooper DA. Effect of therapeutic drug monitoring on outcome in antiretroviral experienced HIV-infected individuals. J Clin Virol 2003; 26: 223–7